Sensus Healthcare Inc (SRTS)

Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026April 23, 2026 5:56 PM
Business Wire
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.


Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.


The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com.


About Sensus Healthcare


Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423949422/en/
Investor Relations Contact

Leigh Salvo

New Street Investor Relations

leigh@newstreetir.com


Original: Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026

SRTS under $10

SRTS new 52 hi

$SRTS -Video Coverage
🧙‍♂️Zidar On Top & Hot Penny Stock~

Wow! What a scam. Really bad report. Now today they are diluting the hell out of it!! I guess I have a tax write off for the end of 2023. This will be under a dollar by June!!

Srts headed back to $3.00

Who’s ready for the biggest run in history?

Looks like it’s gunna tank.

SRTS what a beast

11.86 next shhhh

And This Friday , Green machine

not bad for a wild Friday

How High Can She Fly , DDn were their making rev from

SRTS ready to break to new highs

SRTS break out play.

* * $SRTS Video Chart 02-26-2021 * *

Link to Video - click here to watch the technical chart video

News out, needs to get found. Going much higher

$SRTS news Wednesday got buried under politics. http://www.globenewswire.com/news-release/2021/01/06/2154303/0/en/Holy-Name-Medical-Center-in-Teaneck-New-Jersey-Acquires-Sensus-Healthcare-s-Low-dose-Radiation-Therapy-System-to-Treat-Pneumonia-in-COVID-19-Patients.html http://www.globenewswire.com/news-release/2021/01/06/2154303/0/en/Holy-Name-Medical-Center-in-Teaneck-New-Jersey-Acquires-Sensus-Healthcare-s-Low-dose-Radiation-Therapy-System-to-Treat-Pneumonia-in-COVID-19-Patients.html

$SRTS - Declined unsolicited BO at $4 last summer —> upped reimbursement for SRT use —> SRT used as covid pneumonia treatment + strong balance sheet + new distro in China...low float and thiiinnnn

Email from company regarding form 25 which was for warrants not common stock

Email from IR

The form 25 is related to the expiration of warrants that were originally issued in their IPO. This has nothing to do with the offer to acquire the company, which was rejected by the board.

On Jun 5, 2020, at 1:18 AM

FORM 25 Filed Is buyout taking place? Traders weigh in and voice your opinions.

8k on 6/1/20 ($4 Buyout Offer Turned Down)


This is what i found on form 25


Understanding SEC Form 25
Securities may be delisted from an exchange for various reasons. Bonds may have matured, been called, or redeemed by a company. A company might want to go private by paying cash for all or a substantial portion of its public shares, or perhaps its outstanding securities have been exchanged for cash or another security as part of a takeover. It might just want to voluntarily delist from a national securities exchange or inter-dealer quotation system, in order to suspend or reduce the company’s public reporting obligations under the Exchange Act.

$3.05 Counter Offer Watch From
Buyer !



On May 26, 2020, Sensus Healthcare, Inc. (the “Company”) received an unsolicited offer to acquire all the outstanding shares of the Company at a price of $4.00 per share, in cash. Following consideration by and at the direction of its Board of Directors, the Company has rejected the offer.

Watch For A Higher Buyout Price!

2.95 *** Buyout Rejected 4.00 a share


On May 26, 2020, Sensus Healthcare, Inc. (the “Company”) received an unsolicited offer to acquire all the outstanding shares of the Company at a price of $4.00 per share, in cash. Following consideration by and at the direction of its Board of Directors, the Company has rejected the offer.